T-killers (CAR-T therapy)
Many pathogens are located inside the affected cells out of reach for humoral immunity factors (such as antibodies). To cope with intracellular parasites, a separate system of cellular acquired immunity arose, based on the functioning of T-killers. Chimeric receptor T cell therapy is called CAR-T therapy.
Content |
The main articles are:
Killer T cells, or cytotoxic T cells, are white blood cells specializing in the defeat of viruses and tumor cells. There are about five million of them in one teaspoon of blood.
T-killers directly contact damaged cells and destroy them. Unlike NK cells, T-killers specifically recognize a specific antigen and kill only cells with this antigen. There are tens of millions of T-killer clones, each of which is "tuned" to a specific antigen.
In the video below, T-killers kill a cancer cell.
The mechanism of operation of these cells is interesting. Once the T-killer detects the cancer cell, the membrane "fingers" of the lymphocyte test it. After such "identification," the T-killer binds to the cell and injects poisonous proteins (shown in red in the video) into microtubules on its surface. Finally, the white blood cell punctures this surface, allowing the poisonous cargo to destroy the cancer cell.
History
2023
2024: New immunotherapy provides 100% cancer remission in patients
On January 4, 2024, Swiss researchers from the Lausanne Federal Polytechnic School (EPFL) reported new advances in CAR-T cell therapy in the treatment of malignant tumors. Scientists have managed to achieve 100% cancer remission in patients. Read more here.
CAR T therapy coped with lupus and other autoimmune diseases in all patients
On December 9, 2023, the American Society of Hematology (ASH) reported that CAR T therapy had achieved complete drug-free remission in patients with systemic lupus erythematosus and other autoimmune diseases. The findings may offer hope for safe and effective treatment for many people suffering from severe ailments.
CAR T therapy is originally designed to treat blood cancer, in which antibody-producing B cells start dividing uncontrollably. The technology is a method of treating cancer patients with the help of their own immune cells, which are specially modified in laboratory conditions. After infusion, these specially prepared cells function as a tumor-oriented drug.
The aim of the new study was to investigate whether CAR T therapy is effective in autoimmune diseases. Such ailments develop due to the pathological production of autoimmune antibodies or the proliferation of autoaggressive clones of killer cells against healthy tissues of the body. Experts selected 15 patients with severe systemic lupus erythematosus, idiopathic inflammatory myopathy and systemic sclerosis. They received a single infusion of modified immune cells. After that, patients stopped taking immunosuppressants.
Three months after therapy, all patients with systemic lupus erythematosus achieved complete remission and showed no symptoms of the disease. Moreover, as noted, they do not require any additional treatment. People with myopathy who underwent therapy also achieved remission, whereas patients with systemic sclerosis showed significant improvement in symptoms without exacerbation of the disease.[1]
Cases of cancer after CAR-T cell therapy
On November 28, 2023, the U.S. Food and Drug Administration (FDA) initiated a review in connection with the results of clinical studies related to CAR-T cell therapy. Reports suggest that the use of this method may provoke the development of additional malignancies as side effects.
CAR-T-cell therapy is a method of treating cancer patients with the help of their own immune cells, which are specially modified in laboratory conditions. After infusion, these specially prepared cells function as a tumor-targeting drug. By the end of November 2023, the FDA had approved six CAR-T methods: Abecma (idecabtagen vicleucel), Breyanzi (lysocabtagen maraleucel), Carvykti (cyltacabtagen autolecel), Kymriah (tisagenleukleucel), Tecartus (brexukabtagen autolecel) and Yescarta (axicolabtagel). They are designed to treat blood cancers, including lymphomas and some types of leukemia.
The FDA notice says the overall benefits of the listed products outweigh the potential risks from their use. Nevertheless, due to the likelihood of the development of secondary malignancies, the regulator conducts an additional safety check. Based on its results, conclusions will be made about the need to take certain measures.
It is noted that the greatest fears are caused by the Kymriah product of Novartis AG. The regulator's adverse events database indicates that this therapy is associated with much more frequent cases of malignancies than other similar treatments. By the end of November 2023, more than 10 thousand patients received Kymriah therapy, and Novartis did not reveal a causal relationship between the treatment and secondary malignancies.[2]
2022: Unique CAR-T cell therapy in Russia, replacing toxic chemotherapy
As it became known in April 2022, the National Medical Research Center of Hematology and the Dmitry Rogachev National Medical Research Center of Hematology jointly conducted CAR-T therapy in a patient with mantle zone cell lymphoma (a variant of B-cell non-Hodgkin lymphoma). This is the first experience in Russia in using CAR-T as the first line (after targeted therapy) in an adult patient.
According to Kommersant, CAR-T cell therapy is a treatment method based on the use of the patient's own cells. T lymphocytes are extracted from the patient's body using apheresis, a technology that allows blood to be divided into components and a certain number of lymphocytes can be obtained. Their modification is then done so that they can recognize and attack the tumor cells and they are injected back into the patient's body.
]]
The 68-year-old Russian was diagnosed with lymphoma from the cells of the mantle zone, the so-called blastoid version is an extremely aggressive course, explained Evgeny Zvonkov, head of the intensive high-dose lymphoma chemotherapy department of the National Medical Research Center of Hematology. Subsequently, genetic breakdowns associated with absolute resistance to standard chemotherapy were found. Because of this, doctors were forced to apply a targeted effect in the first line, which allows them to bypass the signaling pathway associated with a mutation in the TR53 gene.
According to Zvonkov, the drugs ibrutinib and venetoclax have minimal toxicity, but, as it turned out, are extremely effective.
 | A week later, almost nothing remained of the tumor, instead of 1.5 million white blood cells, 700 became, and the spleen, the size of which was 30 cm, became normal, platelets and hemoglobin recovered. Before us was actually a healthy person, - said Evgeny Zvonkov. |  |
Notes
| The site content is translated by machine translation software powered by PROMT. The machine-translated articles are not always perfect and may contain errors in vocabulary, syntax or grammar. Read original article If you find inaccuracies or errors in the results of machine translation, please write to editor@tadviser.ru. We will make every effort to correct them as soon as possible. |